Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Extracorporeal or ex vivo removal of antibodies or immune...
Reexamination Certificate
2006-04-04
2006-04-04
Saunders, David (Department: 1644)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Extracorporeal or ex vivo removal of antibodies or immune...
C424S810000, C604S005010, C604S005020
Reexamination Certificate
active
07022322
ABSTRACT:
Immunoapheresis treatment for cardiomyopathy comprises passing the patient's plasma over a column having coupled thereto a specific ligand for human immunoglobulin, thereby removing a significant portion of the immunoglobulin from the patient's plasma, and then reinfusing the plasma to the patient. The invention is the use of a specific ligand for human immunoglobulin in the manufacture of a column having the ligand coupled thereto, the column being useful for immunoapheresis treatment of a patient with cardiomyopathy. The specific ligand binds, and thereby removes, human autoantibodies which are harmful to cardiac tissue such as antibodies against β1-adrenergic receptors, ADP-ATP carriers, α and β myosin heavy chains, and adenine nucleotide translocators. Immunoapheresis treatment using the column results in improvement of hemodynamic parameters such as mean arterial pressure, mean pulmonary pressure, pumonary capillary wedge pressure, right atrial pressure, cardiac output, cariac index, stroke volume index, and systemic vascular resistance.
REFERENCES:
patent: 4223672 (1980-09-01), Terman et al.
patent: WO 91 17171 (1991-11-01), None
patent: 9220811 (1992-11-01), None
patent: WO 93 24158 (1993-12-01), None
patent: WO 95 31727 (1995-11-01), None
Borberg et al, Transfusion Science, 15, 409-418, 1994.
Magnusson et al, Journal of Autoimunnity, 4, 893-905, 1991.
Muller Derlich et al, Immunobiology, vol. 189, Nos. 1-2, p. 237, 1993.
Schwimmbeck et al. European heart Journal, vol. 11 (Abstr. Suppl. 1), p. 280, 1990.
Muller et al., “Simultaneous reduction in anti-betal adrenoceptor autoantibodies and an improvement in cardiac function during mechanical support . . . ”, CIRCULATION, vol. 92, No. 8 Suppl., Oct. 15, 1995.
Muller et al., “Reduction in beta2-receptor autoantibody level in patients with idiopathic dilated cardiomyopathy during mechanical cardiac . . . ”, Journal of The American College of Cardiology, No. special issue, Feb. 1995; p. 23A.
Wllukat et al., “Removal of antibodies in dilated cardiomyopathy by immunoadsorption”, International Journal of Cardiology, vol. 54, No. 2, May 1996, pp. 191-195.
Baumann Gert
Brehme Stefan
Felix Stephan
Koll Robert
Müller-Derlich Jutta
Condino Debra D.
Edwards Lifesciences Corporation
Saunders David
Schulman B. Aaron
LandOfFree
treatment of cardiomyopathy by removal of autoantibodies does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with treatment of cardiomyopathy by removal of autoantibodies, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and treatment of cardiomyopathy by removal of autoantibodies will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3594568